We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Oyster Point’s first FDA-approved commercial product launched in 2021 and leverages our nicotinic acetylcholine receptor (nAChR) domain expertise. We are also exploring other potential applications for our approved product and are developing additional product candidates for ophthalmic diseases.
Data Provided by Refinitiv. Minimum 15 minutes delayed.